Latest news with #Albany
Sustainability Times
12 hours ago
- Science
- Sustainability Times
'Hidden for 80 Million Years': Rare Dinosaur Egg Reveals Stunning Secrets Through Groundbreaking CT Scan Analysis
IN A NUTSHELL 🦖 Paleontologists conducted CT scans on a rare dinosaur egg and a Giant Beaver skull at the New York State Museum. and a at the New York State Museum. 🔬 The scans revealed hidden internal structures, offering new scientific insights into these ancient species. into these ancient species. 🤝 The collaboration between the museum and Albany Medical Center highlights the importance of interdisciplinary efforts in paleontological research. in paleontological research. 📚 The findings promise to enhance our understanding of prehistoric life and serve as a valuable resource for educators and researchers. In an exciting collaboration between the New York State Museum and Albany Medical Center, paleontologists have embarked on a groundbreaking journey to uncover ancient secrets hidden within two rare artifacts: a dinosaur egg and a Giant Beaver skull. Utilizing advanced CT scanning technology, experts aim to delve deeper into the internal structures of these artifacts, offering a glimpse into the past that promises to revolutionize our understanding of these extinct species. This initiative not only highlights the importance of interdisciplinary collaboration but also sets the stage for future discoveries that will enrich our knowledge and appreciation of natural history. Unraveling the Mysteries of the Duck-billed Dinosaur Egg The dinosaur egg under scrutiny is believed to belong to the Hadrosaur family, commonly known as duck-billed dinosaurs, which roamed the earth during the late Cretaceous Period. This egg, estimated to be between 70-80 million years old, provides a unique opportunity to explore the reproductive habits of these fascinating creatures. Although its exact origin is thought to be Asia, Hadrosaurs had a wide distribution, including regions in the Northeastern United States. The CT scan, while not definitive in identifying an embryo due to insufficient density variations, has revealed encouraging results. The egg's structural integrity appears intact, and the presence of a small internal cavity has opened new avenues for research. Scientists are eager to investigate this cavity further to determine its contents or significance. This discovery underscores the importance of ongoing paleontological research, which continues to shed light on the lives of extinct creatures. Remarkably, a recent discovery in Mongolia revealed a massive hadrosaurid footprint measuring approximately 35 inches across, further exemplifying the continuous advancements in our understanding of these ancient beings. As researchers delve deeper into the mysteries of the dinosaur egg, the potential for groundbreaking insights into the life and times of Hadrosaurs remains immense. '8,000 Dinosaur Bones Found': Canada's Fossil Graveyard Reveals One of the Most Terrifying Prehistoric Mass Death Sites Ever Unearthed Unlocking Secrets of the Rare Giant Beaver Skull The second artifact subjected to CT scanning is the skull of a Giant Beaver, scientifically known as Castoroides ohioensis. This extinct Pleistocene epoch rodent rivaled the size of a modern black bear, making it one of the largest beavers to have ever existed. The New York State Museum's collection includes the first described skull of this species, marking it as an invaluable specimen for scientific study. The examination of the Giant Beaver's skull through CT scans promises to yield unprecedented insights into its anatomy. Researchers anticipate discovering more about its diet, behavior, and evolutionary journey during the Ice Age. The extinction of the Giant Beaver, likely around 10,000 years ago, is attributed to a combination of climatic shifts and habitat destruction, offering a cautionary tale of environmental change. Dr. Robert Feranec, Director of Research and Collections, emphasizes the significance of these scans in enhancing our understanding of extinct creatures. The expertise of the scientists involved, combined with cutting-edge technology, allows for a closer look at these ancient relics, shedding light on their reproductive and developmental patterns. As research continues, the potential for new revelations about the Giant Beaver remains high. This Prehistoric Armored Fish From 465 Million Years Ago Could Be the Key to Understanding Why Our Teeth Still Hurt Collaborative Efforts in Scientific Exploration The success of the CT scans is a testament to the power of collaboration between different scientific disciplines. The partnership between the New York State Museum's paleontologists and radiological experts at Albany Medical Center has been pivotal in advancing this research. Such collaborations are crucial for unlocking and preserving the rich history of New York State and, by extension, our understanding of prehistoric life. The insights gained from the scans serve as momentum, propelling researchers closer to unveiling the secrets within the dinosaur egg and Giant Beaver skull. As museum researchers continue to analyze the data in the coming weeks and months, the anticipation for new findings grows. These efforts not only contribute to our scientific knowledge but also inspire future generations to appreciate and explore the wonders of natural history. Michael Mastroianni, Interim Deputy Commissioner of Cultural Education, highlights the long-term value of the information obtained from these scans. It will serve as an invaluable resource for researchers and educators, ensuring that the knowledge gained will benefit scientific inquiry and public education for years to come. 'Lost City Rises Again': Submerged Indian Metropolis Stuns Archaeologists and Forces a Rethink of All Human Civilization Timelines The Future of Paleontological Discovery As the research unfolds, the potential discoveries from the dinosaur egg and Giant Beaver skull hold significant promise for the field of paleontology. These findings could redefine our understanding of extinct species, offering a more comprehensive view of their lives and environments. The use of advanced technology like CT scanning represents a leap forward in our ability to explore and document ancient history with unprecedented detail. The continued analysis of these artifacts will likely yield new insights, further enriching our comprehension of the natural world. As we reflect on these scientific advancements, we are reminded of the importance of preserving our past to inform our future. The collaboration between institutions and the dedication of researchers play a vital role in ensuring that these treasures from the past are not only studied but celebrated. What other hidden secrets might be waiting to be discovered within the collections of museums around the world, and how might they shape our understanding of our planet's history? Our author used artificial intelligence to enhance this article. Did you like it? 4.3/5 (26)
Globe and Mail
3 days ago
- Business
- Globe and Mail
Diabetes Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Therapies, Medication, NDA Approval, IND, Mechanism of Action, Route of Administration by DelveInsight
Diabetes Companies are vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. (Albany, USA) DelveInsight's, ' Diabetes Pipeline Insight 2025 ' report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Diabetes Pipeline. Dive into DelveInsight's comprehensive report today! @ Diabetes Pipeline Outlook Key Takeaways from the Diabetes Pipeline Report In April 2025, Gan & LEE Pharmaceuticals announced a study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin. In March 2025, Dong-AST Co. Ltd announced a study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control. In March 2025, Novo Nordisk A/S announced a study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine doctors can already prescribe). Participants will either get faster aspart or insulin aspart (NovoRapid®) - which treatment is decided by chance. DelveInsight's Diabetes pipeline report depicts a robust space with 200+ active players working to develop 200+ pipeline therapies for Diabetes treatment. The leading Diabetes Companies such as vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. Promising Diabetes Therapies such as Aspirin, DA-2811, Forxiga, TG103, and others. Stay ahead with the most recent pipeline outlook for Diabetes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs Emerging Diabetes Drugs Profile Cadisegliatin: vTv Therapeutics Cadisegliatin, also known as TTP399, is an innovative oral medication developed by vTv Therapeutics, designed as a liver-selective glucokinase activator. It aims to serve as an adjunctive therapy to insulin for individuals with type 1 diabetes (T1D). This drug has been recognized for its potential to improve glycemic control by enhancing hepatic glucose uptake and glycogen storage independently of insulin, addressing a critical need in diabetes management. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes. LY-3209590: Eli Lilly and Company Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes. THDB0206: Tonghua Dongbao Pharmaceutical BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of Diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Diabetes. CPL207280: Celon Pharma CPL207280 is a novel G-protein-coupled receptor 40 (GPR40) agonist under development for the treatment of Diabetes. CPL207280 acts as an agonist for GPR40, a receptor that plays a crucial role in enhancing glucose-stimulated insulin secretion from pancreatic beta cells. This mechanism is particularly beneficial for T2D patients, as it can improve glycemic control without the risk of hypoglycemia, a common side effect associated with other diabetes medications. Currently, the drug is in the Phase II stage of development to treat Diabetes. XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, which means it mimics the action of the GLP-1 hormone that is released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination therapies with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetes. KN056: Suzhou Alphamab Co., Ltd. KN-056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. for the treatment of Diabetes. KN-056 functions as a GLP-1R modulator, which means it targets the glucagon-like peptide-1 receptor. GLP-1 is a hormone that plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. By modulating the GLP-1 receptor, KN-056 aims to improve glycemic control in patients with Diabetes. Currently, the drug is in the Phase I stage of its clinical trial for the treatment of Diabetes. The Diabetes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Diabetes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetes Treatment. Diabetes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Diabetes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetes market Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline. Access DelveInsight's detailed report now! @ New Diabetes Drugs and Medication Diabetes Companies vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Diabetes Products have been categorized under various Molecule types such as, Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Diabetes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Diabetes Market Drivers and Barriers Scope of the Diabetes Pipeline Report Coverage- Global Diabetes Companies- vTv Therapeutics, Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical and others. Diabetes Therapies- Aspirin, DA-2811, Forxiga, TG103, and others. Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Diabetes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Diabetes: Overview Pipeline Therapeutics Therapeutic Assessment Diabetes– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Cadisegliatin: vTv Therapeutics Drug profiles in the detailed report….. Mid-Stage Products (Phase II) CPL207280: Celon Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) KN056: Suzhou Alphamab Co., Ltd. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Diabetes Key Companies Diabetes Key Products Diabetes- Unmet Needs Diabetes- Market Drivers and Barriers Diabetes- Future Perspectives and Conclusion Diabetes Analyst Views Diabetes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +19193216187 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
Reuters
4 days ago
- Politics
- Reuters
US Supreme Court boosts Catholic challenge to NY abortion insurance coverage
June 16 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by the Catholic Diocese of Albany to a 2017 New York state regulation that generally requires employer-sponsored health insurance plans to cover abortions. The justices threw out a 2024 New York Court of Appeals decision that the state regulation did not violate the rights of religious employers under the U.S. Constitution's protections for free exercise of religion. The Supreme Court directed the lower court to reconsider the matter in light of its June 5 ruling that revived a bid by an arm of a Catholic diocese in Wisconsin for a religious exemption from that state's unemployment insurance tax. Both the Wisconsin and New York regulations allow exemptions for religious employers who primarily employ and serve people of their own faith. The Albany Diocese has said New York's exemption is too narrow because it does not include organizations that have a broader purpose such as serving the poor or that employ or serve a large number of people who did not share their religion. The rule adopted by New York's Department of Financial Services exempts non-profit entities whose primary purpose is the "inculcation of religious values" and serving co-religionists. The rule was made into law by the state legislature in 2022, though the law was not challenged in the lawsuit. The diocese filed suit to challenge the regulation. The state Court of Appeals previously ruled against the diocese in 2020, citing an earlier case before the same court upholding a New York contraception coverage requirement with a similar religious exemption. In 2021, the Supreme Court ruled that the city of Philadelphia could not refuse to place foster children with a Catholic agency that turned away same-sex couples as would-be foster parents, and then ordered the New York court to reconsider the abortion coverage case in light of that ruling. The state Court of Appeals last year said the Supreme Court's ruling did not change the outcome because it was narrowly focused on the facts of that case and did not overturn the longstanding precedent that neutral, generally applicable laws can sometimes restrict religious expression. The Supreme Court, with its 6-3 conservative majority, has taken an expansive view of religious rights in a series of rulings in recent years. That includes the June 5 decision, which said that courts must subject laws or regulations demonstrating a preference for certain religions over others to the most stringent constitutional test, known as strict scrutiny.
Yahoo
5 days ago
- Politics
- Yahoo
Still a chance for NY packaging reduction bill to reach assembly floor
A spokesperson for the leader of the New York State Assembly said it's possible lawmakers in Albany will consider a packaging reduction bill supported by local and statewide environmental advocates before the session ends next week. Whether there will be enough votes to actually approve the Packaging Reduction and Recycling Infrastructure Act remains to be seen. In response to questions from the Niagara Gazette this week, Thomas O'Neil White, a spokesperson for assembly Majority Leader and Buffalo Democrat Crystal Peoples-Stokes, said the bill is not on the agenda yet, but People-Stokes believes it will make it to the floor for a vote before the end of the session, which is expected to close either Tuesday or Wednesday. 'It depends on what is in the bill as it could change a few times before coming up for a vote,' O'Neil White said. Supporters of the bill said on Friday that 'possible' consideration was not good enough. Renae Kimble, president of the Niagara Falls chapter of the NAACP, who joined local and statewide environmental advocates in calling for the bill's passage earlier this week, described the bill on Friday as 'vitally important' to protect the health of every Western New Yorker. 'Given the toxic legacy of Western New York, we need all of the assembly members to lead and support this bill,' Kimble said. 'The bill has already been amended 26 times at the request of various businesses. The Senate has already adjourned meaning there is no time for further amendments, so we need the assembly to vote on the bill, as is, before they also adjourn in the coming days.' The act would impose a 30% reduction on packaging statewide over the next 12 years and calls for the phasing out of 17 toxic chemicals currently found in various forms of packaging. Supporters say it would cut plastic waste, improve public health and reduce costs for taxpayers. They also warn that remnants from plastic waste impact health and wellness, resulting in higher costs of care borne by New York residents and local governments. Environmental advocates say plastic waste is particularly harmful to the environment, especially the Great Lakes, including Lake Ontario. Kimble said the impacts have proven particularly harmful to minorities living in cities like Niagara Falls and Buffalo. 'Black, brown, disabled, and marginalized members of our communities across the state have been subjected to the deadly effects of toxic pollutants due to the disproportionate amount of contaminated packing waste sent to landfills and incinerators in heavily populated Environmental Justice communities,' Kimble said. Supporters of the bill's passage have also noted that existing state and local policies, such as the State Agency Green Purchasing Executive Order, and retailer programs, such as Walmart, already work to avoid the use of high-hazard toxic chemicals in packaging and products. Patti Wood, executive director of Grassroots Environmental Education, said the bill builds upon Governor Paterson's 2008 State Agency Green Purchasing Executive Order, which requires state agencies to prioritize the procurement of products. The former governor's order requires the state to reduce or eliminate the health and environmental risks from the use or release of toxic substances, minimize the risks of the discharge of pollutants into the environment and minimize the volume and toxicity of packaging. 'This bill builds on smart green purchasing state and local policies that have been requiring manufacturers to avoid highly toxic chemicals in their products and packaging and 'green the marketplace' since 2008,' Wood said.
Yahoo
6 days ago
- Sport
- Yahoo
Albany Ninja Lab Announces 2025 Summer Camp Programs
Albany Ninja Lab opens registration for 2025 Summer Camps with Taylor Treadgold, featuring skill-based ninja training, flexible scheduling, and a supportive environment for young athletes across the Capital Region. Albany, New York--(Newsfile Corp. - June 14, 2025) - Albany Ninja Lab is excited to announce its 2025 Summer Camp in Albany, offering a dynamic and obstacle-based athletic experience for children throughout the Capital Region. These weeklong sessions, led by coach Taylor Treadgold, will run from July through August, focusing on structured physical challenges, team-building, and individual 12,000-square-foot facility features state-of-the-art obstacle training equipment, including warped walls, salmon ladders, quintuple steps, and a dedicated parkour area for free-running activities. Albany Ninja Lab promotes an inclusive environment centered around positive reinforcement, a zero-bullying policy, and strong community support-ensuring every participant has a chance to grow in a safe and encouraging space. Warped walls To view an enhanced version of this graphic, please visit: This Summer Camp in Albany is designed to accommodate busy family schedules. Weekly sessions run Monday through Friday and are available in three formats: morning (9:00 a.m.-12:00 p.m.), afternoon (1:00 p.m.-4:00 p.m.), and full-day (9:00 a.m.-4:00 p.m.). Campers are grouped by ability to ensure developmentally appropriate challenges. Each session maintains an 8:1 camper-to-instructor ratio with a maximum of 48 participants per session. All coaches are CPR certified and background-checked. Instruction focuses on age-appropriate drills and long-term athletic development, helping children build strength, coordination, and confidence. Albany Ninja Lab Announces 2025 Summer Camp Programs To view an enhanced version of this graphic, please visit: Each day of camp follows a consistent schedule that balances instruction, obstacle challenges, and active play. Morning sessions begin with open gym time and continue with structured classes and skills training. Afternoon sessions follow a similar format tailored to their time block. Campers participate in obstacle navigation, fitness games, and teamwork activities throughout the camps for kids will be held during the following weeks in 2025: July 7-11, July 14-18, July 21-25, July 28-August 1, August 4-8, August 11-15, and August 25-29. Half-day sessions are available at $75 for single drop-in days or $299 for a full week. Full-day sessions are priced at $115 per day or $400 per week. Quintuple steps To view an enhanced version of this graphic, please visit: Registration is now open for all summer sessions. For more information or to enroll, families can contact Albany Ninja Lab directly. About the company: Albany Ninja Lab is the Capital Region's premier obstacle training facility, located in a modern 12,000-square-foot gym in Albany, NY. The gym features a wide range of ninja and parkour obstacles suitable for all ages and abilities. Committed to creating an inclusive and empowering space, Albany Ninja Lab emphasizes positive reinforcement, a zero-tolerance bullying policy, and strong community engagement. The facility offers youth classes, birthday parties, open gym access, and seasonal programs focused on helping participants develop strength, confidence, and resilience through movement-based training. Contact Info:Name: Daniel KirchnerEmail: info@ Albany Ninja LabAddress: 161 Washington Avenue Ext Suite 104b Albany, New York 12205Phone: 518-608-4725Website: Social Media:Facebook: Video URL: To view the source version of this press release, please visit
